Baytril 2.5% Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

baytril 2.5% oral solution

bayer limited - enrofloxacin - oral solution - 2.5 percent weight/volume - enrofloxacin - cattle, other birds, reptiles - antibacterial

Baytril Piglet Doser 0.5% Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

baytril piglet doser 0.5% oral solution

bayer limited - enrofloxacin - oral solution - 5.0 milligram(s)/millilitre - enrofloxacin - pigs - antibacterial

ENRO-K 100 mg/ml Solution for use in drinking water Ireland - English - HPRA (Health Products Regulatory Authority)

enro-k 100 mg/ml solution for use in drinking water

laboratorios karizoo s.a. - enrofloxacin - oral solution - 100 milligram(s)/millilitre - enrofloxacin - chickens, turkeys - antibacterial

Enro-Sleecol 100 mg/ml oral solution for chickens and turkeys Ireland - English - HPRA (Health Products Regulatory Authority)

enro-sleecol 100 mg/ml oral solution for chickens and turkeys

krka, d.d., novo mesto - enrofloxacin - oral solution - 100 milligram(s)/millilitre - enrofloxacin - chickens, turkeys - antibacterial

HYPERHEP B S/D SOLUTION Canada - English - Health Canada

hyperhep b s/d solution

grifols therapeutics llc - hepatitis b immunoglobulin (human) - solution - 220unit - hepatitis b immunoglobulin (human) 220unit - serums

APO-RANITIDINE SOLUTION Canada - English - Health Canada

apo-ranitidine solution

apotex inc - ranitidine (ranitidine hydrochloride) - solution - 75mg - ranitidine (ranitidine hydrochloride) 75mg - histamine h2-antagonists

HYPERHEP B S/D SOLUTION Canada - English - Health Canada

hyperhep b s/d solution

grifols therapeutics llc - hepatitis b immunoglobulin (human) - solution - 220unit - hepatitis b immunoglobulin (human) 220unit - serums

HYPERHEP B S/D SOLUTION Canada - English - Health Canada

hyperhep b s/d solution

grifols therapeutics llc - hepatitis b immunoglobulin (human) - solution - 220unit - hepatitis b immunoglobulin (human) 220unit - serums

LEPTOSHIELD VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

leptoshield vaccine

zoetis australia pty ltd - leptospira interrogans serovar pomona formol culture; leptospira borgpetersenii serovar hardjo type hardjobovi; thiomersal - parenteral liquid/solution/suspension - leptospira interrogans serovar pomona formol culture vaccine-microbial active 0.0 p; leptospira borgpetersenii serovar hardjo type hardjobovi vaccine-microbial active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - cattle | deer | goat | sheep | beef | billy | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock | calf | capra - leptospirosis | urinary shedding | l. hardjo | l. interrogans | l. pomona | l. tarassovi

ENALAPRIL MALEATE ORAL SOLUTION- enalapril maleate solution United States - English - NLM (National Library of Medicine)

enalapril maleate oral solution- enalapril maleate solution

bionpharma inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate oral solution is indicated for the treatment of symptomatic heart failure, usually in combination with diuretics and digitalis. in these patients, enalapril maleate oral solution increases survival and decreases the frequency of hospitalization. in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate oral solution decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. enalapril is contraindicated in patients with: - a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme (ace) inhibitor. [see warnings and precautions ( 5.2)] - hereditary or idiopathic angioedema. [see warnings and precautions ( 5.2)] do not co-administer aliskiren with enalapril in patients with diabetes [see drug interactions ( 7.2)] . enalapril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see warnings and precautions ( 5.2)] . risk summary enalapril can cause fetal harm when administered to a pregnant woman. use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. when pregnancy is detected, discontinue enalapril as soon as possible. the estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. in the general u.s. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations adverse reactions in the fetus or in neonates with a history of in utero exposure to enalapril maleate. use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, oligohydramnios, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death. in the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. perform serial ultrasound examinations to assess the intra-amniotic environment. fetal testing may be appropriate, based on the week of pregnancy. patients and physicians should be aware, however, that oligohydraminos may not appear until after the fetus has sustained irreversible injury. closely observe infants with histories of in utero exposure to enalapril for hypotension, oliguria, and hyperkalemia. if oliguria or hypotension occurs in neonates with a history of in utero exposure to enalapril, support blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function. risk summary enalapril and enalaprilat have been detected in human breast milk. because of the potential for severe adverse reactions in the breastfed infant, including hypotension, hyperkalemia, and renal impairment, advise women not to breastfeed during treatment with enalapril. neonates with a history of in utero exposure to enalapril maleate if oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure. pediatric patients with heart failure or asymptomatic left ventricular dysfunction  safety and effectiveness of enalapril have not been established in pediatric patients with heart failure or asymptomatic left ventricular dysfunction. this drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. ace inhibitors, including enalapril, as monotherapy have an effect on blood pressure that is less in black patients than in non-blacks. use a lower initial dose of enalapril in patients undergoing hemodialysis and in patients whose egfr is ≤ 30 ml/min [see clinical pharmacology ( 12.3)] .